Quick Answer
ADMA BIOLOGICS, INC. reported Long-Term Debt of $69.33 million for fiscal year 2025.
ADMA BIOLOGICS, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $69.33M | -4.2% |
| 2024 | $72.34M | — |
| 2019 | $0.00 | -100.0% |
| 2018 | $2.76M | +0.0% |
| 2017 | $2.76M | +54.2% |
| 2016 | $1.79M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.08M | — | -3.1% |
| December 31, 2024 | $72.34M | — | — |
| September 30, 2019 | $0.00 | -100.0% | — |
| June 30, 2019 | $0.00 | -100.0% | — |
| March 31, 2019 | $0.00 | -100.0% | -100.0% |
| December 31, 2018 | $2.76M | +0.0% | +0.0% |
| September 30, 2018 | $2.76M | +54.2% | +0.0% |
| June 30, 2018 | $2.76M | +54.2% | +0.0% |
- ADMA BIOLOGICS, INC. showed a decrease of -4.2% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2025 period, ADMA BIOLOGICS, INC.’s long-term debt has grown by 3773.2% (from $1.79 million to $69.33 million).
- The most recent figure is from ADMA BIOLOGICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: